Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma by unknown
BioMed Central
World Journal of Surgical Oncology
ssOpen AcceResearch
Topoisomerase II trapping agent teniposide induces apoptosis and 
G2/M or S phase arrest of oral squamous cell carcinoma
Jinzhong Li1, Wantao Chen*1, Ping Zhang1 and Ningyi Li2
Address: 1Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Stomatology, Shanghai, 
200011, P. R. China and 2Affiliated Hospital, School of Medicine, Qingdao University, Qingdao,266021, P.R.China
Email: Jinzhong Li - lijzh78@sohu.com; Wantao Chen* - chenwantao2002@hotmail.com; Ping Zhang - pingzhang73@hotmail.com; 
Ningyi Li - liny@qdumh.qd.sd.cn
* Corresponding author    
Abstract
Background: Teniposide (VM-26) has been widely used in the treatment of small cell lung cancer,
malignant lymphoma, breast cancer, etc. However, there are few reports on VM-26 against oral
cancers. The present study was designed to identify the effect of VM-26 against oral squamous cell
carcinoma in vitro, and to provide evidence for the feasibility and effectiveness of VM-26 for
application to the patients with oral cancer.
Methods: Human tongue squamous cell carcinoma cell line, Tca8113, was used. Cells were
incubated with different concentrations of VM-26 for a variety of time span. Cisplatin (CDDP) was
employed as a control reagent. MTT assay was used to assess the inhibitory rate of Tca8113
growth. Flow cytometer (FCM), transmission electronic microscope (TEM) and fluorescence
staining were employed for determining the cell apoptotic rate. Cell cycle distribution of Tca8113
incubated with VM-26 was examined by flow cytometer assay. Statistic software (SAS 6.12, USA)
was used for one-way ANOVA.
Results: The IC50 of VM-26 against Tca8113 cells was 0.35 mg/l and that of CDDP was 1.1 mg/l.
The morphological changes of Tca8113 cells were observed with fluorescence microscope and
TEM. Apoptotic morphological feature could be found in the nucleus. Apoptotic rate of Tca8113
cells incubated with 5.0 mg/l of VM-26 for 72 hours was 81.67% and cells waere arrested at S phase.
However, when exposed to 0.15 mg/l of VM-26 for 72 hours, G2/M phase increased from 12.75%
to 98.71%, while the apoptotic rate was 17.38%, which was lower than that exposed to 5.0 mg/l of
VM-26.
Conclusion: VM-26 could significantly induce apoptosis of oral squamous cell carcinoma and
inhibit cell growth. There may be another pathway to induce apoptosis of oral squamous cell
carcinoma cells except for G2/M phase arrest.
Background
The 5-year survival rate was reported to reach 64.7% for
patients with oral carcinomas, while that for patients at
advanced stages was between 20.0% and 40.0% [1]. As
one of three main therapies, chemotherapy may be a
potential method to improve the survival rate and quality
of life in patients with oral cancer, especially in advanced
cancers. Cancers in oral cavity are different with cancers in
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chemosensitive, and there is still no special anticancer
drug available, which is a hinder for further improvement
of chemotherapeutic treatment against oral cancers.
Topoisomerase II (Topo II) exists ubiquitously in cells
and plays an essential role in DNA replication, transcrip-
tion, chromosome formation and separation of sister
chromatid [2-4]. Because of its essential role in cell
growth, cell-cycle, as well as the high expression in prolif-
erating cells, this enzyme is an ideal target for cancer
chemotherapeutic drug [5,6]. Virtually every form of can-
cers that can be cured by systemic chemotherapy were
always treated with regimens that focus on (or at least
contain) drugs targeted to Topo II [7]. Indeed drugs tar-
geted to Topo II are now indispensable components of
systemic chemotherapy schedule which could effectively
cure several known types of human cancers. Teniposide
(4'-demethylepipodophyllotoxin thenylidene-beta-D-
glucoside, VM-26) is a podophyllotoxin derivative and
was found to be able to stabilize DNA-Topo II complex in
DNA replication, thus damage the DNA and induce cellu-
lar apoptosis. It has been shown that in the treatment
against small cell lung cancer, malignant lymphoma,
breast cancer and ovarian cancer, etc through both clinical
findings from chemotherapy results and in vitro chemo-
sensitivity test of tumor specimen, anti-tumor effect on
VM-26 was stronger than other chemotherapeutic drugs
[8-10]. However, there were yet few reports on VM-26
against oral cancers. The purpose of this present study was
to explore the apoptosis and concomitant cell cycle pro-
gression of Tca8113 cell treated with VM-26, and to pro-
vide evidence for the feasibility and effectiveness of VM-
26 for application to oral cancers clinically.
Methods
Cell line
Tca8113 cell line derived from a patient with tongue squa-
mous cell carcinoma, was used in this study and cultured
in RPMI 1640 medium supplemented with 10% calf
serum, 200,000 u/l penicillin and 200,000 u/l streptomy-
cin. Cells were cultured in 25 ml culture flasks with 2 ×
105 cells/ml, in humidified atmosphere with 5% CO2 at
37°C.
Drugs and reagents
VM-26 (Bristol-Myers Squibb Co. USA, List: 3075–9), was
dissolved in sterile double distilled water to a concentra-
tion of 1 g/l, and stored at -20°C. Cisplatin (CDDP, Qilu
Co. China, List: 9908012) was dissolved to a final concen-
tration of 0.1 g/l. 5.0 g/l MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] was purchased
from Sigma Chemical-reagent Company. Annexin V-FITC
Kit (Becton-Dickinson Co., USA) was used in this experi-
ment.
MTT assay
Logarithmically growing Tca8113 cells were trypsinized
and made into single cell suspension then plated in 96-
well culture plate at a concentration of 5 × 104 cells/well,
eight columns for VM-26 and seven columns for CDDP in
each plate, 3 wells in each column. After 24 hours of incu-
bation, the medium of the 3 wells in each column were
replaced with medium containing VM-26 of 0.15 mg/l,
0.5 mg/l, 1.5 mg/l, 5.0 mg/l, 15 mg/l and 45 mg/l or
CDDP of 0.1 mg/l, 0.3 mg/l, 1.0 mg/l, 3.0 mg/l and 9.0
mg/l, respectively. Blank control wells were added
medium without drugs. Cells were then cultured for
another 24 hours, 48 hours, 72 hours, 96 hours and 120
hours. The supernatants were removed and 20 μl MTT
solution was added in each well, followed with another 4
hours of culture. The supernatants were discarded care-
fully and 200 μl dimethyl sulphoxide (DMSO, Sigma,
USA) was added and shaken vigorously to dissolve the
purple precipitation formation. Optical density (OD) of
each well was tested using Spectrophotometer (Bio-Tek
instruments INC.) with a wavelength of 450 nm. The
experiment was repeated in triplicate. The inhibitory rate
(IR) of cell growth was calculated with the following for-
mula:
IR = [(1-ODt)/ODc] × 100%
(ODt: OD of cells in treated groups; ODc: OD of cells in
control groups).
Cell fluorescence staining
Cells were incubated with VM-26 of 0.15 mg/l, 0.5 mg/l,
1.5 mg/l, 5.0 mg/l and 15 mg/l for 24 hours, 48 hours, 72
hours, 96 hours and 120 hours, respectively, then washed
twice in phosphate buffered saline (PBS) and centrifuged
at 1000 rpm for 10 minutes. Cell concentration was
adjusted as 1 × 106 cells/ml. 10 μl of fluorescence dye EB/
AO was added in 100 μl cell suspension, followed with 30
minutes of incubation in dark. Cells were then observed
under fluorescence microscope. Nuclei of dead cells were
dyed red while nuclei in live cells were dyed green.
Observation of cell ultrastructure using TEM
Cells were cleansed using dimethylarsinic sodium, and
fixed immediately with 2% glutaraldehyde for 30 min-
utes. The cells were then fixed with 1% osmium tetroxide
for 2 hours at 4°C, dehydrated in ethanol of gradient con-
centrations, displaced twice using epoxy dimethylmeth-
ane, and permeated using 618 embedding solution.
Ultrastructure of cell was observed and recorded using
TEM Equipment (H-500, Japan).
Cell apoptosis assay
The cells were incubated with VM-26 of 0.15 mg/l, 1.5
mg/l, 5.0 mg/l and 15 mg/l for 12 hours, 24 hours, 36Page 2 of 7
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and medium supernatant were collected, washed twice
with cold PBS, resuspended in 100 μl 1 × binding buffer
(contained in Annexin V kit), stained with 5 μl Annexin V-
FITC and 5 μl PI, and tested using flow cytometer (FACS-
calibur, Becton-Dickinson Co., USA).
Cell-cycle assay
Tca8113 cells were treated with VM-26 of 0.15 mg/l, 1.5
mg/l, 5.0 mg/l and 15 mg/l for 12 hours, 24 hours, 36
hours, 48 hours and 72 hours, respectively. Then the cells
were harvested, fixed in cold 70% ethanol for 30 minutes,
and resuspended in 1 ml PBS. The cell suspensions were
treated using 100 μl RNase of 1 g/l for 30 min, and stained
with 100 μl PI of 50 mg/l in dark for 30 minutes, and then
the cells were tested using FCM. The cell cycle distribution
was analyzed using ModFit LT 3.0 software.
Statistics
Data were analyzed with one-way ANOVA using SAS sta-
tistical software (6.12, TS20).
Results
Dose-dependent manner of VM-26 and CDDP against 
Tca8113 cells
0.5 mg/l of VM-26 showed significantly inhibitory effect
in a dose-dependent manner. Cells shrank and round-
shaped, accompanied with increasingly plasma vacuoles
formation. Incubated with 0.5 mg/l of VM-26 (1/30 of
average plasma concentration) for 72 hours, cell growth
was inhibited significantly, and 83.58% Tca8113 cells
were dead. IC50 of VM-26 was 0.35 mg/l (figure 1). How-
ever, 0.3 mg/l of CDDP (1/10 of average plasma concen-
tration) could not inhibit cell growth significantly. The
IC50 of CDDP was 1.1 mg/l (figure 2).
Time-dependent manner of VM-26 and CDDP against 
Tca8113 cells
Both VM-26 and CDDP showed growth inhibitory
potency to Tca8113 cells in a time-dependent manner.
VM-26 of 5.0 mg/l significantly inhibited the proliferation
of Tca8113 cells. The inhibitory rate was 40.65% at 24
hours. As time went on, the inhibitory rate reached 80.9%
at 72 hours and 92.1% at 96 hours. VM-26 had a stronger
inhibitory potency than CDDP at the similar level of
plasma concentration at any time span (figure 3).
Apoptosis assay of Tca8113 cells
Fluorescence staining intuitively showed the inhibitory
effect of VM-26. The nuclei of control Tca8113 cells
stained with EB/AO dye were green (figure 4A). Treated
with VM-26 of 0.5 mg/l for 24 hours, some nuclei became
red and some dyed into yellow. With the concentration of
VM-26 increasing or time lapsing, more cells became red,
which confirmed the time-dependent and dose-depend-
ent manner of VM-26 against Tca8113 cells. Figure 4B
show the dead cells after incubation with 5.0 mg/l of VM-
26 for 72 hours.
The ultrastructure changes during cell death were
observed compared with the feature of blank control cells
(figure 4C) using TEM. The cells treated with VM-26
showed typical apoptotic phenomenon. The nucleus
became smaller, karyoplasm was concentrated and karyo-
theca was crimpled, chromosome condensed into a semi-
lunar shape clinging to the karyotheca and the cellular
membrane (figure 4D). The results indicated that Tca8113
cells were killed by VM-26 through apoptotic induction.
CDDP inhibited the proliferation of Tca8113 cells dose-dependently (cells we e treated for 72 hours) according to the results of MTT assayFigure 2
CDDP inhibited the proliferation of Tca8113 cells dose-
dependently (cells were treated for 72 hours) according to 
the results of MTT assay. The IC50 of CDDP was 1.1 mg/l. 
The figure was the representative of three independent 
experiments.
VM-26 inhibited the proliferation of Tca8113 cells in a dose-dependent way (cells wer  treated for 72 hours) accor ing to the results of MTT assayFigure 1
VM-26 inhibited the proliferation of Tca8113 cells in a dose-
dependent way (cells were treated for 72 hours) according 
to the results of MTT assay. The inhibitory rates reached pla-
teau when the dose of VM-26 increased to 1.5 mg/l. The 
IC50 of VM-26 was 0.35 mg/l. The figure was the representa-
tive of three independent experiments.Page 3 of 7
(page number not for citation purposes)
World Journal of Surgical Oncology 2006, 4:41 http://www.wjso.com/content/4/1/41Most Tca8113 cells were killed through apoptosis in a
dose-dependent manner, which increased significantly
with the increase of VM-26 concentration. Compared the
4 concentrations, 5.0 mg/l of VM-26 or 15 mg/l seemed to
induce similar apoptosis in Tca8113 cells, which indi-
cated that 5.0 mg/l of VM-26 was effective in inducing
apoptosis (figure 5). Cells exposed to 0.15 mg/l of VM-26
seemed to just begin apoptosis at 36 hours, which approx-
imate to population doubling time of Tca8113 cells (38.8
hours). However, cells treated with 5.0 mg/l of VM-26
began apoptosis at 24 hours and only 3.57% was viable
after 72 hours (figure 6).
Cell-cycle distribution
Tca8113 cells exposed to VM-26 showed cell cycle arrest
in a time-dependent manner. 98.71% of cells were
arrested at G2/M phases after treated with 0.15 mg/l of
VM-26 for 72 hours, (figure 7). Apoptosis of cells seemed
to be induced through the G2/M phase arrest. While
Tca8113 cells treated with 5.0 mg/l of VM-26 cell cycle
was arrested mainly in S phase, and higher apoptotic rate
occurred in this group (shown in figure 6 and figure 8).
The morphological changes of Tca8113 cells treated with VM-26Figure 4
The morphological changes of Tca8113 cells treated with VM-26. Figure A showed the blank control cells were dyed green 
using EB/AO stained, figure B showed the cells exposed to 5.0 mg/l of VM-26 for 72 hours were dyed red. Figure C showed the 
feature of blank control cells, figure D showed the apoptotic phenomenon of Tca8113 cells exposed to 5.0 mg/l of VM-26 for 
48 hours, chromosome condensed into a semilunar shape and clung to the karyotheca (TEM × 4000).
5.0 mg/l of VM-26 and 1.0 mg/l of CDDP inhibited the prolif-eration of Tca8113 cells ti e-dependently accor ing to the results of MTT ass yFig re 3
5.0 mg/l of VM-26 and 1.0 mg/l of CDDP inhibited the prolif-
eration of Tca8113 cells time-dependently according to the 
results of MTT assay. VM-26 played potent inhibiting effect 
on the proliferation of Tca8113 cells compared with CDDP 
with the parallel plasma concentrations. The figure was the 
representative of three independent experiments.Page 4 of 7
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was arrested at G2/M phase, while in another group (con-
taining 5.0 mg/l of VM-26) cells were arrested at S phase
(figure 8).
Discussion
Topo II has two isomers, TopoIIα and Topo IIβ. Topo IIα
is cell-cycle regulated and is abundant in proliferating
cells while Topo IIβ predominates in quiescent cells [11].
High expression of Topo IIα in tumor tissue is a common
phenomenon, and Topo IIα is gradually regarded as a sign
to judge the extent of tumor cell proliferating [12-14].
Topo II poisons can be classified as DNA-intercalating
drug and DNA-nonintercalating drug. The former can
damage DNA through inserting the plane portion of its
molecular structure, such as the ring of purine or pyrimi-
dine, into the double strands of DNA where Topo II bind-
The cells were harvested and analyzed with propidium iodide staining to assess cell cycle istribution by FACS analysis andthe results w re expressed a  mean ± SD of three indepe -ent experimentsFigure 8
The cells were harvested and analyzed with propidium iodide 
staining to assess cell cycle distribution by FACS analysis and 
the results were expressed as mean ± SD of three independ-
ent experiments. Overlay of cell cycle distributions of 
Tca8113 cells exposed to 5.0 mg/l of VM-26. The line in yel-
low, green, red, light blue and brown indicated the cell cycle 
distributions of control cells, and of cells treated with VM-26 
for 12 hours, 24 hours, 36 hours and 48 hours, respectively. 
The cell cycle of Tca8113 cells were obviously arrested at S 
phase as time lapsed.
The apoptosis of Tca8113 cells were induced by VM-26 in a time-dependent manner ac ording to the r sults of Annexin-V/PI ssayFigure 6
The apoptosis of Tca8113 cells were induced by VM-26 in a 
time-dependent manner according to the results of Annexin-
V/PI assay. 5.0 mg/l of VM-26 demonstrated more apoptosis-
inducing effect on Tca8113 cells than 0.15 mg/l did. The 
results were expressed as mean ± SD of three independent 
experiments.
The apoptosis of Tca8113 cells were induced by VM-26 in a dose-de endent manner (for 48 hours) ac ording to the results f Annexin-V/PI assayFig re 5
The apoptosis of Tca8113 cells were induced by VM-26 in a 
dose-dependent manner (for 48 hours) according to the 
results of Annexin-V/PI assay. 5.0 mg/l of VM-26 induced sim-
ilar apoptotic rate as 15 mg/l of VM-26 did. The results were 
expressed as mean ± SD of three independent experiments.
Overlay of cell cycle distributions of Tca8113 cells exposed to 0.15 mg/l of VM-26 fo  a variety of time spanFigure 7
Overlay of cell cycle distributions of Tca8113 cells exposed 
to 0.15 mg/l of VM-26 for a variety of time span. The cells 
were harvested and analyzed with propidium iodide staining 
to assess for cell cycle distribution by FACS analysis. The line 
in yellow, green, red, light blue, brown and blue indicate the 
cell cycle distributions of control cells, and of cells treated 
with teniposide for 12 hours, 24 hours, 36 hours, 48 hours 
and 72 hours, respectively. The cell cycle of Tca8113 cells 
were obviously arrested at G2/M phase as time lapsed. The 
results were expressed as mean ± SD of three independent 
experiments.Page 5 of 7
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broken DNA double strands, which lead cell to death
eventually. However, the mechanism of non-intercalating
drug killing tumor cells is still unclear. VM-26 is a kind of
non-intercalating TopoII poison. Generally speaking,
drug that can inhibit Topo IIα is also capable of inhibiting
Topo IIβ. However, most drugs, especially non-intercalat-
ing drugs, are more effective on Topo IIα while intercalat-
ing drugs are more effective on Topo IIβ [15]. Chen et al
[16] applied 8 drugs (CDDP, 5-Fu, PYM, Taxol, VM-26, E-
ADM, VDS and MTX), to test the chemosensitivity of 140
oral cancer specimens before chemotherapy, finding the
average inhibitory rate of VM-26 against tumor cells
reached 63.76% while the inhibitory rates of other 7 drugs
were less than 30.0%. These oral squamous cell carci-
noma specimens seemed not sensitive to E-ADM which is
an intercalating Topo II poison.
CDDP was used as a positive control drug because it was
in wide clinical use and regarded as a standard chemother-
apeutic drug. We chose experimental concentration of
these two drugs according to their average plasma concen-
tration because it determined their clinical effects. Both
the MTT and the FCM assay indicated that, at 5.0 mg/l
concentration, the potency of VM-26 inhibiting Topo II
and inducing apoptosis reached plateau. In any case, 5.0
mg/l (1/3 average plasma concentration [17]) VM-26
could induce approximate maximum inhibitory effect on
Tca8113 cells in vitro. We found that 5.0 mg/l of VM-26
could inhibit oral cancer cells significantly after 72 hours
incubation; the inhibitory rate reached 92.1% at 120
hours, which was much higher than those of CDDP at the
1/3 average plasma concentration. VM-26 inhibits the
growth of tumor cell in an obvious dose-dependent and
time-dependent manner.
The typical apoptotic phenomenon was found in Tca8113
cells treated with VM-26 by TEM, and also, apoptosis were
induced by VM-26 both dose-dependently and time-
dependently. There are many pathways for cells apoptosis,
including PKA/camp pathway, T cell receptor pathway,
dead receptor pathway and Fas/TNFR1 associated path-
way. Mo et al [4] found that the ability of these DNA Topo
II inhibitors including VM-26 activating FasL promoter
and inducing FasL expression, was correlated with their
ability to cause DNA damage. When these permanent
DNA breaks were present in sufficient numbers, they ini-
tiated a series of apoptosis events that ultimately culmi-
nated in cell death [7].
G2 phase arrest was a common phenomenon found in
mammalian cells when they were treated with most DNA-
damaging reagents [18]. Such G2 arrest has been pro-
posed to be due to induction of G2 checkpoint machinery
that allows damaged DNA to be repaired before cells
move to the next cell cycle stage [19,20]. Chen et al [21]
reported that cells treated with VM-26 of higher dosage
stopped the cell cycle in S phase, but they found the cells
at last be arrested in the G2/M phase if the time of incuba-
tion with drug was prolonged and assumed such S phase
inhibition should be a kind of S phase retardation other
than arrest. The present study showed only VM-26 of 0.15
mg/l could significantly arrest cells in G2/M phase, while
VM-26 of 1.5 mg/l, 5.0 mg/l and 15 mg/l tended to stop
cell progression in S phase, and initiated significant apop-
tosis concomitantly. Thus, this kind of apoptosis was not
triggered by G2 checkpoint machinery. This study found
apoptosis of cells incubated with VM-26 of 5.0 mg/l was
much more than that of cells with VM-26 of 0.15 mg/l,
that is, much more cells died in the S phase than cells did
in G2/M phase. So, apoptosis of Tca8113 cells incubated
with VM-26 might not be induced by G2/M phase arrest,
apoptosis could be induced before cells reached G2 check-
point. Cells do not always get into G2/M phase when
treated with VM-26. There may be another pathway to
induce apoptosis of oral carcinoma cells except traditional
G2/M phase arrest.
Conclusion
The present study showed that Tca8113 cells were sensi-
tive to VM-26 and provided evidences for applying VM-26
in oral cancer chemotherapy. The results also showed that
low dose and high dose of VM-26 worked in different way
and there existed other ways except for G2/M phase arrest.
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